CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
This is an observational study for people with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. The study aims to understand the long-term safety and how well standard treatments for SLE work in real-world settings. Researchers will collect information from you and your rheumatology doctor during your regular clinic visits. This will help them learn more about SLE, how treatments affect it, and improve care for patients. You can join if you are at least 18 years old and have been diagnosed with SLE by a rheumatologist. The study is currently recruiting participants.
- Study design
- This is an observational study planning to enroll 1000 participants. It collects information from participants and their doctors during routine clinical care.
- What's involved
- You will have data collected during your routine clinical visits. You may also be asked to provide a blood sample for an optional biorepository.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your health information will be collected every 6 months for 10 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- SLE epidemiology and presentation,Every 6 months for 10 years
The major clinical outcome include an assessment of the epidemiology of Systemic Lupus Erythematosus; to better understand the presentation and natural history.
- SLE management, and outcomesEvery 6 months for 10 years
The major clinical outcome include an assessment of the epidemiology of Systemic Lupus Erythematosus; to better understand the management and outcomes.